Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current ...

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...